TY  - JOUR
T1  - Multimodal Treatment Superiority in Osteoarthritis: Insights from a Dagestani Cohort Study (2022-2024)
A1  - Valeriia Valerievna Volobueva
A1  - Aida Sulitdinovna Ayubova
A1  - Karina Ernestovna Urudzheva
A1  - Kamilla Ernestovna Urudzheva
A1  - Guzel Islamovna Zeynalova
A1  - Khabib Sagdulaevich Dzhairulaev
A1  - Islam Omargadzhievich Ibragimov
A1  - Selima Badrudievna Idalova
JF  - Journal of Biochemical Technology
JO  - J Biochem Technol
SN  - 0974-2328
Y1  - 2025
VL  - 16
IS  - 2
DO  - 10.51847/cV7BDzw1om
SP  - 49
EP  - 56
N2  - This prospective observational study evaluated the efficacy and safety of different treatment modalities in 240 osteoarthritis (OA) patients (mean age 58.7±9.2 years; 68.3% female) at a diagnostic center in the Republic of Dagestan from 2022 to 2024. Patients were stratified into four treatment groups: NSAIDs (n=72), chondroprotectors (n=60), hyaluronic acid (HA) injections (n=54), and combination therapy (n=54). Primary outcomes included changes in pain intensity (VAS) and functional status (WOMAC) at 12 months. Combination therapy demonstrated superior clinical outcomes, with 41.7% of patients achieving ≥50% pain reduction compared to 22.2% in the NSAID group (p=0.008). Mean WOMAC improvement was significantly greater with combination therapy (-35.2±10.1%) versus monotherapies (p
UR  - https://jbiochemtech.com/article/multimodal-treatment-superiority-in-osteoarthritis-insights-from-a-dagestani-cohort-study-2022-202-jpqlh4edq9shxik
ER  -